Data from the first phase III trial of dupilumab, an antibody that inhibits the signaling of Il-4 and IL-13 proteins, highlighted how this drug changes the structural and histologic characters of EoE and decreases the patients’ symptoms, such as the ability to swallow [147]. Here, IL13 is linked to eosinophilic esophagitis.